Abstract
Type 2 cyclo-oxygenase inhibitors are new anti-inflammatory drugs with better gastrointestinal tolerance than traditional non-steroidal anti-inflammatory drugs. They have no platelet anti-aggregant effects and there is still some discussion as to whether this new therapeutic class has any pro-thrombotic effects. The authors report two cases of myocardial infarction in patients considered to be at low risk treated by type 2 cyclo-oxygenase inhibitors.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adult
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / adverse effects
-
Cyclooxygenase Inhibitors / therapeutic use*
-
Factor V / genetics
-
Female
-
Humans
-
Isoenzymes / antagonists & inhibitors*
-
Male
-
Membrane Proteins
-
Middle Aged
-
Mutation
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / genetics
-
Prostaglandin-Endoperoxide Synthases
-
Thrombolytic Therapy / methods*
-
Tissue Plasminogen Activator / therapeutic use
-
Treatment Outcome
-
Ventricular Function, Left
Substances
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Isoenzymes
-
Membrane Proteins
-
factor V Leiden
-
Factor V
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Tissue Plasminogen Activator